AR089232A1 - Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia - Google Patents
Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemiaInfo
- Publication number
- AR089232A1 AR089232A1 ARP120104706A ARP120104706A AR089232A1 AR 089232 A1 AR089232 A1 AR 089232A1 AR P120104706 A ARP120104706 A AR P120104706A AR P120104706 A ARP120104706 A AR P120104706A AR 089232 A1 AR089232 A1 AR 089232A1
- Authority
- AR
- Argentina
- Prior art keywords
- branched
- linear
- optionally substituted
- halogen atoms
- combination according
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical group C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 abstract 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- -1 3-cyclopropylmethoxy-4-difluoromethoxy-phenyl Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960001727 tretinoin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una combinación caracterizada porque comprende: i) un compuesto de fórmula general (1) en donde: n es 0 ó 1; R¹ y R² pueden ser iguales o diferentes, y se eligen a partir del grupo que consiste en: alquilo C₁₋₆ lineal o ramificado, opcionalmente sustituido con uno o más átomos de halógeno; OR³ en donde R³ es un alquilo C₁₋₆ lineal o ramificado opcionalmente sustituido con uno o más átomos de halógeno o grupos cicloalquilo C₃₋₇; y HNSO₂R⁴ en donde R⁴ es un alquilo C₁₋₄ lineal o ramificado opcionalmente sustituido con uno o más átomos de halógeno, en donde al menos uno de R¹ y R² es HNSO₂R⁴; ii) un retinoide y/o iii) un derivado de arsénico, que se administra en forma simultánea, secuencial o separada. Reivindicación 3: La combinación de acuerdo a la reivindicación 2, caracterizada porque el compuesto de fórmula general (1) es éster 1-(3-ciclopropilmetoxi-4-difluorometoxi-fenil)-2-(3,5-dicloro-1-oxi-piridin-4-il)-etílico de ácido (-)-3-ciclopropilmetoxi-4-metanosulfonilamino-benzoico (C2). Reivindicación 5: La combinación de acuerdo a la reivindicación 4, caracterizada porque el derivado de arsénico es trióxido de arsénico (ATO). Reivindicación 8: La combinación de acuerdo a la reivindicación 7, caracterizada porque el retinoide es ácido aII-trans retinoico (ATRA).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194076 | 2011-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089232A1 true AR089232A1 (es) | 2014-08-06 |
Family
ID=47563345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104706A AR089232A1 (es) | 2011-12-16 | 2012-12-13 | Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20130156865A1 (es) |
| AR (1) | AR089232A1 (es) |
| WO (1) | WO2013087749A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6458957B2 (ja) | 2013-10-22 | 2019-01-30 | チエシ ファルマスティスィ エス．ピー．エー． | Ｐｄｅ４阻害剤の製造方法 |
| WO2015068142A2 (en) * | 2013-11-11 | 2015-05-14 | Cellworks Group, Inc. | Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder |
| CN104730200A (zh) * | 2013-12-20 | 2015-06-24 | 辰欣药业股份有限公司 | 一种用电位滴定法测定罗氟司特含量的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512819A1 (en) * | 2003-01-14 | 2004-07-29 | Altana Pharma Ag | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| WO2009147169A1 (en) * | 2008-06-03 | 2009-12-10 | Universite Paris Diderot-Paris 7 | Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
-
2012
- 2012-12-13 AR ARP120104706A patent/AR089232A1/es unknown
- 2012-12-13 WO PCT/EP2012/075338 patent/WO2013087749A1/en not_active Ceased
- 2012-12-14 US US13/714,938 patent/US20130156865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130156865A1 (en) | 2013-06-20 |
| WO2013087749A1 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2540463T3 (es) | Electrolito híbrido | |
| EP2768539A4 (en) | ANTIMICROBIAL FORMULATIONS WITH PELARGONIC ACID | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR094970A1 (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| MX357131B (es) | Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso. | |
| UY34763A (es) | Inhibidores de la agregación plaquetaria | |
| UY34365A (es) | Compuestos heterociclicos | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY34550A (es) | Bencilpirazoles sustituidos | |
| UY34057A (es) | Inhibidores del virus de la hepatitis c | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| AR094959A1 (es) | Compuestos de imidazo piridina | |
| CO7350620A2 (es) | Nuevos derivados de piridina | |
| UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
| UY33936A (es) | Derivados de fluoro-piridinona útiles como agentesantibacterianos. | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| CR20130539A (es) | Triazolopiridinas | |
| EA201391303A1 (ru) | Амиды n-(1,2,5-оксадиазол-3-ил)-, n-(тетразол-5-ил)- и n-(триазол-5-ил)бициклоарилкарбоновых кислот и их применение в качестве гербицидов | |
| AR089623A1 (es) | Inhibidores de iap | |
| AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos | |
| UA111333C2 (uk) | Спосіб одержання l-аргінінової солі периндроприлу | |
| AR089232A1 (es) | Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia | |
| CR20140114A (es) | Compuestos de benzotiazolona | |
| AR087788A1 (es) | Derivado de acido pirrolidin-3-ilacetico | |
| UY34433A (es) | Compuestos antimicrobianos con carbolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |